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Abstract: Vasculogenic mimicry (VM) is an intratumoral microcirculation pattern formed by
aggressive cancer cells, which mediates tumor growth. In this study, we compiled the evidence
from studies evaluating whether positive VM status can serve as a prognostic factor to patients with
squamous cell carcinoma of the head and neck (HNSCC) or esophagus (ESCC). Comprehensive
systematic searches were conducted using Cochrane Library, Ovid Medline, PubMed, and Scopus
databases. We appraised the quality of studies and the potential for bias, and performed random-effect
meta-analysis to assess the prognostic impact of VM on the overall survival (OS). Seven studies with
990 patients were eligible, where VM was detected in 34.24% of patients. Positive-VM was strongly
associated with poor OS (hazard ratio = 0.50; 95% confidence interval: 0.38–0.64), which remained
consistent following the subgroup analysis of the studies. Furthermore, VM was associated with
more metastasis to local lymph nodes and more advanced stages of HNSCC and ESCC. In conclusion,
this study provides clear evidence showing that VM could serve as a promising prognosticator
for patients with either HNSCC or ESCC. Further studies are warranted to assess how VM can be
implemented as a reliable staging element in clinical practice and whether it could provide a new
target for therapeutic intervention.
Keywords: meta-analysis; prognosis; vasculogenic mimicry; cancer cell-lined vessels; head and neck
squamous cell carcinoma; esophageal squamous cell carcinoma
1. Introduction
Head and neck squamous cell carcinoma (HNSCC) remains one of the most common and deadly
cancers worldwide [1]. HNSCC encompasses a group of aggressive tumors that occur throughout the
oral cavity, hypopharynx, oropharynx, nasopharynx, or larynx [2,3]. They primarily develop through
Cells 2020, 9, 507; doi:10.3390/cells9020507 www.mdpi.com/journal/cells
Cells 2020, 9, 507 2 of 16
chemically induced (i.e., tobacco and alcohol abuse) or virally induced (i.e., human papillomavirus)
carcinogenesis [2,4]. The incidence and mortality of HNSCC are rapidly growing in different geographic
regions, including many European and Nordic countries [5]. Some variants of HNSCC, such as basaloid
SCC, are characterized by a biphasic pattern of growth and have an aggressive clinical behavior [6].
Esophageal cancer ranks seventh in terms of incidence and sixth in mortality [1]. Several studies have
shown that HNSCC is often accompanied by esophageal squamous cell carcinoma (ESCC) [7]. HNSCC
and ESCC share broad similarities, such as cellular origin and tumorigenesis, in addition to their early
dissemination and dismal prognosis [2,8].
Cancer metastasis is the main leading cause of cancer-associated morbidity and mortality, which
accounts for about 90% of cancer-specific deaths [9]. In spite of the multimodality approach in the
management of HNSCC patients, the overall survival (OS) rate is low, particularly when presented
with lymph node metastasis (LNM) and/or recurrence [3,10]. Indeed, a better understanding of cancer
biology is essential to develop more effective treatments that will target, for instance, the mechanisms
underlying tumor growth and metastasis.
Vasculogenic mimicry (VM) was first introduced in 1999 to indicate a remarkable feature of
aggressive melanoma cells to generate vessel-like, blood-containing channels which facilitate tumor
perfusion regardless of surrounding endothelial blood vessels [11,12]. Clinically, VM is commonly
assessed in patient samples by immunohistochemical (IHC) analysis of periodic acid–Schiff (PAS)
positive, and CD31 or CD34 negative vessel-like structures [13]. PAS stains basement membranes
while CD31 and CD34 are regarded as endothelial cell markers. The importance of VM stems from the
ability of certain rapidly-growing tumors to link fulfilment of the nutritional needs with metastatic
progression [14,15]. VM significantly associates with worse prognosis in cancer patients, and hence
it represents an attractive target for novel anticancer drug discovery [14]. Moreover, VM appears to
drive distant metastases of breast cancer cells and simultaneously promotes the passage of red blood
cells and nutrients into the tumoral tissue [15]. However, some studies have also shown that VM is not
significantly associated with cancer prognosis, albeit such patients exhibited shorter OS compared
with VM-free patients [16,17]. Based on the growing interest in VM as a novel therapeutic target in
cancer, clarifying its impact on prognosis will enhance its utility as a biomarker. Therefore, to address
this objective, we conducted a systematic review to identify, critically appraise, and synthesize the
evidence from studies that have so far investigated the association between VM and the prognosis of
patients with HNSCC or ESCC. We specifically evaluated whether immunodetection of VM serves as a
prognostic factor of the survival of these patients.
2. Materials and Methods
2.1. Protocol and Registration
Prior to undertaking the systematic review, we developed a protocol for the work, which was
registered in the international prospective register of systematic reviews PROSPERO (https://www.
crd.york.ac.uk/prospero/) with the following identification number: CRD42019139244. The protocol
was based on PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)
guidelines [18,19].
2.2. Eligibility Criteria
We included original research articles that investigated the relationship between VM and the
survival outcomes of patients with HNSCC or ESCC. We excluded review articles, case reports, case
series, and reports lacking survival data. The detailed inclusion and exclusion criteria are listed in
Table 1.
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Table 1. Inclusion and exclusion criteria applied in this review.
Inclusion Criteria Exclusion Criteria
• Original research articles • The retrieved records were:
# case reports
# reviews
# letters
• Human histological tissue samples • Articles in which results were based on animal
models or tests
• Patients diagnosed with HNSCC/ESCC • Articles in language other than English
• Studies reported the association between VM
expression and the survival outcomes
• Insufficient information of the correlation
between clinical features and/or
survival outcomes
HNSCC, head and neck squamous cell carcinoma; ESCC, esophageal squamous cell carcinoma; VM, vasculogenic mimicry.
2.3. Search Strategy
We conducted a comprehensive search in four databases, including Cochrane Library, Ovid
Medline, PubMed, and Scopus up to June 17th, 2019, without language restriction. The following
MeSH terms and keywords related to VM were applied: (“vasculogenic mimicry” OR “tumor cell-lined
vessels”) AND (“head and neck neoplasms” OR “head and neck cancer” OR “head and neck squamous
cell cancer” OR “esophageal cancer” OR “esophageal squamous cell cancer” OR “oral cancer” OR
“mouth neoplasms” OR “laryngeal neoplasms” OR “gingival neoplasms” OR “oral leukoplakia”
OR “lip neoplasms” OR “palatal neoplasms” OR “tongue neoplasms” OR “pharyngeal neoplasms”
OR “squamous”). Moreover, we used exploded MeSH terms for each cancer type in Ovid Medline.
The retrieved studies were imported to RefWorks and duplicates were removed. Screening of studies
by title and abstract was next undertaken. Finally, full-text screening and evaluation was performed.
The literature screening was undertaken independently by two reviewers (RH and RA) and a third
reviewer (AS) arbitrated if there were discrepancies.
2.4. Data Extraction and Study Items
We developed a data extraction form, which was used to extract relevant information from
each study. Data extraction was independently performed by two authors (RH and RA), and any
discrepancies were resolved by consensus-based discussion with a third reviewer (AS). From each
study, we extracted the following key information: first author’s name, year of publication, country,
tumor information (type, size, and location), type of the samples, total number of patients, number of
positive-VM samples, main findings, methods used to detect VM, antibody information, criteria used
to define VM, outcome measures, and estimates of prognosis (such as hazard ratio (HR) with their
respective 95% confidence interval (95% CI) and p values).
2.5. Assessment of Reporting Quality and Risk of Bias
The quality of reporting in included studies was assessed according to the reporting
recommendations for tumor marker prognostic studies (REMARK) guidelines [20]. From the REMARK
checklist, we adapted the following six essential items as they were deemed pertinent for our
study: (1) patient samples; (2) clinical data; (3) immunostaining; (4) prognostic data; (5) statistical
analysis; and (6) classical prognostic factors. The applied REMARK parameters are listed in Table S1.
The Meta-Analysis of Statistics Assessment and Review Instrument tool (MAStARI) was utilized to
evaluate the risk of bias in the included studies [21]. Ten questions were independently applied in each
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study by two reviewers (RH and RA). For each question, the answers were expressed as yes, no, unclear,
or not applicable as illustrated in Table S2. Accordingly, the risk of bias was categorized as high (i.e.,
the study is carrying high risk of bias) when answers contain ≤49% of “yes” score, moderate (i.e., the
study is carrying moderate risk of bias) when answers contain 50–69% of “yes” score, or low (i.e., the
study is carrying low risk of bias) when answers contain ≥70% of “yes” score. The “not applicable”
questions were not included when calculating the percentage of “yes” scores. Any discrepancies were
resolved by discussion between three authors (RH, RA, and AS). Such discrepancies resulted from
overlooking of data or due to misunderstanding of information, and thus they were easily resolved
without too much discussion.
2.6. Data Synthesis and Statistical Analysis
We produced a descriptive table, as shown in Table 2, to summarize the characteristics as well
as the quality of the included studies based on the REMARK framework [20]. We employed both
narrative and quantitative synthesis to summarize the evidence from the studies. For the quantitative
synthesis, we performed random-effects meta-analysis through the DerSimonian–Laird estimate of
the variance of the effect sizes to pool estimates from the studies that we judged to be reasonably
homogenous with regards to their consistency in methodology and definitions. The weight assigned
to the studies in meta-analyses were based on the inverse variance method in which the weight given
to each study contributing to the meta-analysis is the variance of the effect estimate (that is, weight = 1
divided by the square of the standard error of the effect estimate). Based on the inverse variance
weighting mechanism, larger studies (usually with smaller standard errors) receive more weight than
smaller studies (which have larger standard errors). Out of the seven studies included in the review,
meta-analysis was possible only for four studies [22–25]. We excluded the studies by Liu et al. and Xu
et al. from the meta-analyses because they did not provide effect estimates for the influence of VM
on survival [26,27]. We excluded the study by Lin et al. from the meta-analyses because it estimated
only disease-free survival (DFS) but not OS [28]. Secondly, it was also based on the same cohort as the
study by Wang et al. [22], therefore, including it would mean the inclusion of two studies from the
same participants.
To perform the meta-analyses, some recalculations were performed when necessary. For instance,
some studies looked at the impact of VM positivity (using VM negativity as the reference) on survival,
while some studies looked at the impact of VM negativity (using VM positivity as the reference).
Therefore, in order to have a consistent independent variable and reference group for VM, we changed
the reference groups for all studies that have looked at VM negativity (using VM positivity as the
reference) to VM positivity (using VM negativity as the reference). We did this by dividing the value
one by the HRs and the accompanying 95% CI from the relevant studies. In this way, we ensured
that all studies included in the meta-analysis have the same reference group and are estimating the
same effect, thus comparability of effects between studies is ensured. We performed two sets of
meta-analyses: one in which the four studies were included in the same analysis; and one in which we
divided the studies into two subgroups (HNSCC and ESCC). We quantified any potential heterogeneity
between studies in the pooled estimates using the I2 statistic, which is a measure (range 0%–100%)
that quantifies the percentage of variance in the pooled estimates that is attributable to differences
in estimates between the meta-analyzed studies. The between-study variance was estimated using
a Tau-squared (T2) statistic derived from the DerSimonian–Laird approach. All tests were 2-sided,
and p < 0.05 was considered statistically significant. Analyses were performed using Stata release 14
(StataCorp. 2015. Stata Statistical Software: Release 14. StataCorp LP, College Station, TX, USA).
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3. Results
3.1. Study Selection
In total, our database searches yielded 117 records, of which 67 were duplicate records, leaving
50 articles that further screened for their eligibility. After screening by titles and abstracts, 41 articles
were excluded for not meeting the inclusion criteria. The full-texts of the remaining nine articles were
subsequently screened, of which seven records were included in this systematic review, as shown in
Figure 1.Cells 2020, 9, x 5 of 16 
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3.2. Study Characterist cs
The included articles were published between 2008 and 2018 and presented data from patients
with SCC in the oral cavity proper, larynx, nasopharynx, and esophagus. The immunostaining in these
Cells 2020, 9, 507 6 of 16
studies was performed on formalin-fixed paraffin-embedded samples. The sample sizes varied from
40 to 203, with a total of 990 patients from all studies. Two studies investigated VM in ESCC patients
(n = 277), while the other five studies included patients with HNSCC (n = 713). Two studies were based
on the same participants and were conducted on laryngeal squamous cell carcinoma (LSCC) samples
from the same recruited cohort (from January 1990 to January 2003) and in the same institution [22,28].
Characteristics of the included studies are summarized in Table 2.
Table 2. Characteristics of the included studies.
Study Country Tumor Type TumorStage/Size
No. of
Cases
No. of VM+
Cases
Compliance to
REMARK †
[26] Taiwan OSCC T1–T4I–IV 112 41 (36.60%) Lacked items No. 1–3, 5, 6
[22] China LSCC T1–T4≤3, >3 cm 203 44 (21.67%) Lacked item No. 3
[28] China LSCC T1–T4I–IV 168 37 (22.02%) Lacked item No. 3
[23] China ESCC I–IV 160 78 (48.75%) Fulfilled all items
[24] China ESCC I–III 117 56 (47.86%) Fulfilled all items
[25] China OSCC I–IV≤2, ≤4, >4 cm 190 60 (31.57%) Lacked item No. 3
[27] China NPC I–IV 40 23 (57.50%) Lacked items No. 3, 5
OSCC, oral squamous cell carcinoma; LSCC, laryngeal squamous cell carcinoma; ESCC, esophageal squamous cell
carcinoma; NPC, nasopharyngeal carcinoma; VM+, positive vasculogenic mimicry. † The reporting quality of the
eligible studies was assessed according to the REMARK guidelines [20].
3.3. Quality and Bias Assessment
Two studies fulfilled all of the six REMARK-adapted checklist items [23,24]. Five studies lacked
one or more items as illustrated in Table 2. Based on the MAStARI assessment [21], five studies were
classified as having a low risk of bias [22–25,28]. However, the study by Liu et al. was evaluated as
carrying a moderate risk of bias as only 50% of the questions were addressed as “yes” [26]. One study
was classified as bearing high risk of bias, mainly because they lacked critical information regarding
questions 1 through 4, and thus had only a 25% “yes” score [27]. Further details can be found in
Table S2.
3.4. Identification of VM in HNSCC/ESCC Patients
In all the studies, VM was identified by the IHC double staining method. In the first published
report, authors defined VM as positive pancytokeratin, to highlight tumor cells, and negative CD34
lining [26]. In the rest of studies, VM was identified as positive-PAS and negative CD31 or CD34 lumens.
In addition, three studies highlighted additional criteria using hematoxylin-eosin staining, including
absence of hemorrhage, necrosis, or perivascular inflammatory cell infiltrate [22,25,28]. The presence
of red blood cells in the VM-lumen was indicated by two studies [23,26]. Morphologically, the VM
channels established different forms, ranging from straight, curved, or branched patterns. Importantly,
such positive vessel-like structures were detected in all the studies, with a total of 339 positive-VM
patients (34.24%). The VM-identification methods and antibodies are summarized in Table 3.
3.5. Association between VM and Clinicopathological Factors
Liu et al. revealed that VM was significantly correlated with more LNM in oral squamous cell
carcinoma (OSCC) patients (p = 0.006) [26]. In a larger OSCC cohort, Wu et al. revealed a significantly
positive correlation between VM and tumor size, grade, LNM, and TNM (tumor, node, and metastasis)
stages (r = 0.447; p < 0.001) [25]. In the retrospective study undertaken by Wang et al., VM was
significantly higher in the advanced stages (III and IV) than in the primary ones (I and II) (27.97%
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vs. 12.94%; 0.010). In addition, VM was more frequently observed in LSCC patients with local LNM
(p = 0.003) as well as in the advanced histopathological grades (p < 0.0001) [22]. This was in agreement
with a study by Lin et al., which concluded a positive correlation between VM and more advanced
pTNM stages (p = 0.024), more LNM (p = 0.003), and worse histopathological grade (p < 0.0001) [28].
Two studies examined the correlation between VM and clinicopathological features in ESCC cohorts.
Chai et al. reported significant associations between VM and positive LNM (p < 0.001), presence of
serosa infiltration (p < 0.001), and more progressive pTNM stages (p < 0.001) [23]. However, Zhang et al.
found that VM was correlated with the TNM stages (p = 0.003) but not with the other clinicopathological
elements of ESCC patients [24].
3.6. Survival Endpoints
Several survival endpoints were reported in the eligible studies, as shown in Table 4. Four studies
reported data regarding the association between VM and OS [22–25]. Two studies defined OS as the
time from the date of first biopsy to the date of cancer-related deaths [23,24]. Chai et al. reported the
OS of (VM+/VM−) in ESCC patients as 28.038/66.452 (months), while Wu et al. found the ratio in OSCC
patients was 41.1(±16)/58.9(±14.5) [20,22]. DFS was reported as the primary endpoint in one study [26],
and with OS in two studies [22,24]. In addition to DFS, Lin et al. also adopted metastasis-free survival
and local-recurrence free survival as endpoints in their study [28].
3.7. Prognostic Value of VM in HNSCC/ESCC Patients
Individually, each study reported that VM positivity (compared to VM negativity) was associated
with poorer survival, i.e., positive-VM individuals were more likely to die earlier than those with
negative-VM status. When the studies were pooled together in a meta-analysis, the HR for OS was 0.50
(95% CI 0.38–0.64), as shown in Table 5. The I2 value for the heterogeneity between the studies was
0% and the p-value associated with this was 0.575. In the subgroup analyses, in which studies based
on HNSCC and ESCC were analyzed separately, the worse OS among individuals with positive VM
compared those with negative VM remained consistent, although OS was lower in the ESCC subgroup
(HR 0.40; 95% CI 0.26–0.63) than in the HNSCC subgroup (HR 0.55; 95% CI 0.40–0.74), as shown in
Table 5.
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Table 3. Summary of vasculogenic mimicry identification methods.
Study Method Tissue Reagent Information VM Definition Additional Criteria
[26] IHC, EnVisionDoublestain FFPE
CK: (Mo, MC), Dako
CD34: (Mo, MC), Dako CK
+/CD34− lumens RBCs in lumens
[22] HE, IHC double staining FFPE
CD31: (Mo), Zhongshan
Biotechnology
PAS: Department of Pathology,
Tianjin Hospital
CD31−/PAS+ loops around
cancer cells, with/without RBCs
tumor cell-lined; no
hemorrhage, necrosis,
perivascular inflammatory cell
infiltrate
[28] HE, IHC double staining FFPE
CD31: (Mo), Zhongshan
Biotechnology
PAS: Department of Pathology,
Tianjin Hospital
CD31−/PAS+ loops around
cancer cells, with/without RBCs
HE: no signs of hemorrhage,
necrosis, or perivascular cell
infiltrate
[23] IHC double staining FFPE CD34: (Mo, MC), AbcamPAS: ND
CD34−/PAS+ vessel-like
structures surrounded by tumor
cells in different forms (straight,
curved or branched patterns)
RBCs in channels; few
necrotic/inflammatory cells
near the channels
[24] HE, IHC double staining FFPE CD34: (Rb, MC), AbcamPAS: ND
CD34−/PAS+ lumens composed
of tumor cells -
[25] IHC double staining FFPE CD34: (Mo, MC), AbcamPAS: ND
CD34−/PAS+ small vessel-like
structures
No necrosis or hemorrhage near
VM
[27] IHC double staining FFPE CD34: (Rb, MC), AbcamPAS: Sigma-Aldrich
CD34−/PAS+ channels with a
lining of tumor cells on the
external wall
No ECs on the inner wall
CK, pancytokeratin; ECs, endothelial cells; RBCs, red blood cells; Mo, mouse antihuman; Rb, rabbit antihuman; MC, monoclonal antibody; VM, vasculogenic mimicry; HE, hematoxylin-eosin
staining; PAS, periodic acid–Schiff; ND, not disclosed; FFPE, formalin-fixed paraffin-embedded.
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Table 4. Summary of the reported prognostic data and interpretation of the main findings.
Study End-Point Adjusted Analysis Adjusted Factors Results Interpretation
[26] DFS - - VM correlates significantly with poor survival
[22]
OS HR = 2.117, p = 0.003 VM, recurrence, TNM stage,
radiotherapy
VM is related to pTNM stage, LNM. VM adversely
predicted OS and DFS95% CI = 1.286–3.425
DFS -
[28]
DFS HR = 2.57, p = 0.003
VM, recurrence, radiation
VM was an adverse prognosticator for DFS and
MFS by univariate survival analyses. VM is
independent prognostic factor for only DFS
95% CI = 1.388–4.757
MFS -
LRFS -
[23] OS HR = 0.458, p = 0.0495% CI = 0.217–0.9681
Gender, age, site, gross
morphology, size, DIF, LNM,
serosa infiltration, pTNM, VM,
HIF-1a, E-cad
VM was significantly correlated with LNM,
infiltration, pTNM staging, and 5-year OS of ESCC
patients.VM is independent risk factors of patients
with ESCC
[24]
OS HR = 0.369, p = 0.001
pTNM, DIF, TIN expression,
VM
VM indicates poor OS and DFS.
VM is significant independent prognostic
predictors in ESCC
95% CI = 0.207–0.658)
DFS -
[25] OS HR = 1.674, p = 0.01095% CI = 1.131–2.476 LGR5, VM, TNM, LNM
VM was positively related to tumor size, grades,
LNM, TNM stages, and inversely with patients OS
[27] PFS - - VM formation was associated with a poorprognosis in NPC patients
DFS, disease-free survival; DIF, differentiation; ESCC, esophageal squamous cell carcinoma; LGR5, leucine-rich repeat-containing G-protein coupled receptor 5; LNM, lymph node metastasis;
LRFS, local recurrence free survival; MFS, metastasis-free survival; OS, overall survival; PFS, progression-free survival; TIN, tumor-infiltrating neutrophil; VM, vasculogenic mimicry.
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Table 5. Meta-analysis of the association between VM and OS.
Study No. of Cases Age Range (Years) Age Median (Years) Hazard Ratio (95% CI) Relative Weight (%)
ALL STUDIES
[23] 160 32–87 - 0.46 (0.22–0.97) 11.81
[22] 203 32–77 66 0.47 (0.29–0.77) 26.55
[25] 190 26–86 61 0.60 (0.40–0.89 41.81
[24] 117 46–80 63 0.37 (0.21–0.66) 19.82
Pooled overall estimate 0.50 (0.38–0.64) 100
Heterogeneity measures I-squared = 0.0% (p = 0.575); Tau-squared = 0.00
Subgroup Analyses of the Association between VM and OS in HNSCC and ESCC Studies
HNSCC STUDIES
[22] 203 32–77 66 0.47 (0.29–0.77) 38.84
[25] 190 26–86 61 0.60 (0.40–0.89 61.16
Pooled overall estimate 0.55 (0.40–0.74) 100
Heterogeneity measures I-squared = 0.0% (p = 0.449); Tau-squared = 0.00
ESCC STUDIES
[23] 160 32–87 - 0.46 (0.22–0.97) 37.33
[24] 117 46–80 63 0.37 (0.21–0.66) 62.67
Pooled overall estimate 0.40 (0.26–0.63) 100
Heterogeneity measures I-squared = 0.0% (p = 0.649); Tau-squared = 0.00
ESCC, esophageal squamous cell carcinoma; HNSCC, head and neck squamous cell carcinoma; OS, overall survival; VM, vasculogenic mimicry.
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4. Discussion
This systematic review and meta-analysis summarized the results of seven clinical studies
involving SCC of the head, neck, and esophagus, and represented a total of 990 patients, of which
339 (34.24%) had positive-VM status. All the studies showed that positive-VM immunoreactivity is
associated with a decreased probability of overall survival, so that patients with positive-VM were more
likely to die compared with negative-VM patients. This was further confirmed when we separately
analyzed HNSCC and ESCC studies, as such a shorter survival rate was still evident with positive-VM
patients. Furthermore, a positive VM status in these studies was commonly associated with worse
prognostic clinicopathological factors, such as LNM and TNM stage.
Cancer growth and distant dissemination are associated with worse prognosis and both rely
on adequate blood supply [29]. Indeed, angiogenesis, which is regulated by a number of diffusible
angiogenic factors, plays a vital role in promoting tumor nourishment and, subsequently, tumor
development and metastasis [30,31]. VM is another non-angiogenic pattern of tumor vascularization,
which refers to the ability of tumor cells to create their own vessel-like channels and to function as
endothelial-like cells (ELC) [30,32]. In fact, this highlights the multidirectional extent of phenotypic
plasticity in aggressive tumor cells, which is harnessed to ensure sufficient, non-lymphogenic, blood
perfusion and subsequent tumor growth and metastasis [30]. We illustrate the difference between
angiogenesis and VM in Figure 2.
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alterna ive non-angiogenic vascularization method; (E) tumor cells star to generate new patterned
vessel-like anastom s s; (F) these new tumor cell-lined chann s invade host vessels and inc ease
nutrient retrieval to nourish umor tissue.
The most important strengths of our study include the relatively low level of inter-study
heterogeneity regarding VM definiti n, immunodetection assays, clinicopathological features, and
the key findings. We had a comprehensive search of eligible studies with t e search proposal and
outline of the review processes developed in protocol, which was registered in PROSPERO prior
to perf rming th systematic review. However, we also acknowledge some limitations, such as the
limited number of studies which might reflect the novelty of the VM concept. We were also ompelled
to exclude certain st i s from the meta-analysis because they lacked th adjusted an lysis or due to
sample overlap [22,26,28]. Five studies did not provide all of the r commended information related
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to the staining protocol, which highlights the need to implement REMARK guidelines in research
practice, as shown in Table 2. In addition, all the included reports were from China; hence our findings
should be interpreted with caution, as they may not be widely applicable. Nevertheless, VM has been
shown as a strong prognostic factor in different population segments [32]. Although the included
studies provided some criteria for the immunodetection of VM, this method can be complicated by the
presence of empty basement membrane remnants of regressed vessels, which may look confusingly
similar to VM. Therefore, investigators are encouraged to search for new protocols to better characterize
VM structures.
Indeed, our findings are in agreement with previous meta-analysis reports that have shown the
association between VM positivity with decreased probability of patients’ survival in different cancers.
In two recent meta-analysis studies, VM was associated with a more aggressive tumor phenotype and
poor prognosis in patients with breast and gastric cancers [33,34]. In addition, Zhang et al. reported
that VM status can serve as a promising prognostic biomarker in the prognosis of malignant melanoma
patients [35]. In the same direction, another recent meta-analysis showed that positive VM was a reliable
indicator of poor prognosis in digestive cancer patients [36]. In a larger-scale meta-analysis study that
included 15 types of cancers and 3062 patients, VM-positive cancer patients show a poor 5-year OS
compared with VM-negative cases [16]. Importantly, Yang et al. concluded that VM was associated with
statistically significantly poorer OS in head and neck cancer patients [32]. Moreover, VM formation was
regarded as an unfavorable prognostic indicator in hepatocellular carcinoma [37], osteosarcoma [38],
non-small cell lung cancer [39], colorectal cancer [40], and in cutaneous melanoma [41]. Furthermore,
Wang et al. reported a strong positive correlation between VM and distant metastases in salivary
adenoid cystic carcinoma [42].
The mechanisms underlying such a strong association between VM status and patients’ survival
are not clearly understood. However, several potential explanations were suggested, for instance,
that aggressive tumors harness their own VM channels to obtain a functional perfusion pathway,
independently of angiogenic vasculature, and thus enhances their progression and metastasis [15,43].
Hypoxia has also been suggested as a crucial factor in VM development [44]. In this review, two
studies reported a close association between the presence of “cancer cell-lined vessels”, or VM, and
hypoxia-inducible factor-1 alpha (HIF-1α) in OSCC and ESCC [23,26]. Interestingly, hypoxia was
recently shown to induce epithelial–mesenchymal transition, which contributes to cancer progression
via transition of epithelial cells to potent mesenchymal migratory cells, and VM formation [42,45].
Hypoxia was also reported to promote VM through other signaling pathways, such as the extravascular
VE-cadherin and its role in the acquisition of the VM phenotype [46]. In addition, the multi-phenotypic
reciprocity, observed in VM-forming cancer cells, has the capacity to facilitate tumor progression and
metastasis [47,48]. Because of such a phenotypic switch, the VM-forming ELC are different from normal
endothelial cells, rendering the VM channels inherently resistant to conventional anti-angiogenic
therapy [32,49]. More interestingly, antiangiogenic treatment with Bevacizumab induced VM formation
and metastasis in an ovarian cancer model [50]. In fact, antiangiogenic drugs lead to a hypoxic tumor
microenvironment which enhances invasiveness and VM formation [49].
The term “mosaic vessels” was developed by Chang et al. when they noticed that some of the
intratumoral VM lumens were lined by both endothelial cells and tumor cells [51]. Although such
mosaic lumens were observed in less than 5% of the vascular surface area of colon cancer tissue, they
were suggested as important contributors to metastasis and drug delivery [51–53]. It is worthy to note
that none of the included studies have recognized such potential co-localization when identifying the
VM structures. However, it remains unclear whether this pattern was not detected at all or was just
excluded from the VM definition when designing the study.
5. Conclusions
This systematic review and meta-analysis provide clear evidence showing that VM could represent
a promising prognosticator for patients with either HNSCC or ESCC. Moreover, VM was strongly
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associated with cancer differentiation, LNM, and TNM stage, which highlight its putative role in
tumor growth and metastasis. Further mechanistic studies are warranted to uncover the biological
processes through which VM influences survival, as well as an emerging potential therapeutic target in
solid tumors. Prognostic studies on different types of populations are also required to assess how to
implement VM as a reliable staging element in clinical practice.
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